Emerging Role of Radiopharmaceutical Therapy in Oncology: Advances, Challenges, and Future Directions

Clicks: 3
ID: 315585
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #50 of 51 articles by views in jnci cancer spectrum

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Radiopharmaceutical therapy (RPT) has transformed cancer management by enabling systemic delivery of ionizing radiation via molecularly targeted pharmaceutics, complementing external beam radiotherapy (EBRT), which primarily treats localized, radiographically defined lesions. By coupling diagnostic imaging with therapy, in a "radiotheranostic" paradigm, RPT supports patient-specific target selection, dosimetry and on-treatment monitoring. Progress in target discovery, radioligand chemistry and optimization of pharmacokinetics and biodistribution has improved efficacy and safety, culminating in FDA approvals of [177Lu]Lu-PSMA-617 (Pluvicto®) for metastatic castration-resistant prostate cancer (mCRPC) and [177Lu]Lu-DOTA-TATE (Lutathera®) for neuroendocrine tumors (NET). These successes highlight RPT's expanding role across oncology. This review summarizes the evolution of RPT from early clinical milestones to modern regulatory approvals, then surveys emerging radioligands directed at new molecular pathways. We also discuss strategies to enhance therapeutic response including rational combinations with DNA damage response agents such as poly(ADP-ribose) polymerase inhibitors (PARPi) or immunotherapies. Finally, we outline key challenges such as optimal patient selection, dosimetry standardization, therapeutic resistance and access and highlight few ways to accelerate broader clinical integration and continued innovation.
Reference Key
openalex_W7163151957 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Laura Ordas, Sean Foster, Phuc Pham, Andy Ollendorff, Varun Gnanasekar, Mahmoud Toulany, Quaovi H. Sodji
Journal jnci cancer spectrum
Year 2026
DOI
10.1093/jncics/pkag056
URL
https://doi.org/10.1093/jncics/pkag056
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.